Publication

Nilotinib as frontline and second-line therapy in chronic myeloid leukemia: open questions

Publications associées (29)

Safe Implementation of Embedded Software for a Portable Device Supporting Drug Administration

Yann Thoma, Giovanni De Micheli, Wenqi You Dubout, Alena Simalatsar

Poor adherence to medical regimen causes approximately 33% to 69% of medication-related hospitalizations and accounts for $100 billion in annual health care costs. In this paper we address the problem of unintentional non adherence, when patient fails to t ...

IEEE2014

NUP214-ABL1 mediated cell proliferation in T-cell acute lymphoblastic leukemia is dependent on the LCK kinase and various interacting proteins

Oliver Hantschel

The NUP214-ABL1 fusion protein is a constitutively active protein tyrosine kinase that is found in 6% of patients with T-cell acute lymphoblastic leukemia and that promotes proliferation and survival of T-lymphoblasts. Although NUP214-ABL1 is sensitive to ...

Pensiero Scientifico / Ferrata Storti Foundation2014

Mechanisms of resistance to BCR-ABL and other kinase inhibitors

Emel Basak Gencer Akçok, Oliver Hantschel, Orest Kuzyk, Allan Joaquim Lamontanara

In this article, we are reviewing the molecular mechanisms that lead to kinase inhibitor resistance. As the oncogenic BCR-ABL kinase is the target of the first approved small-molecule kinase inhibitor imatinib, we will first focus on the structural and mec ...

Elsevier Science Bv2013

Dissection of the BCR-ABL signaling network using highly specific monobody inhibitors to the SHP2 SH2 domains

Emel Basak Gencer Akçok, Oliver Hantschel, Sandrine Madeleine Suzanne Georgeon

The dysregulated tyrosine kinase BCR-ABL causes chronic myelogenous leukemia in humans and forms a large multiprotein complex that includes the Src-homology 2 (SH2) domain-containing phosphatase 2 (SHP2). The expression of SHP2 is necessary for BCR-ABL-dep ...

National Academy of Sciences2013

Parameterized SVM for Personalized Drug Concentration Prediction

Giovanni De Micheli, Wenqi You Dubout, Alena Simalatsar

This paper proposes a parameterized Support Vector Machine (ParaSVM) approach for modeling the Drug Concentration to Time (DCT) curves. It combines the merits of Support Vector Machine (SVM) algorithm that considers various patient features and an analytic ...

2013

BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia

Oliver Hantschel

Constitutive activation of STAT5 is critical for the maintenance of chronic myeloid leukemia (CML) characterized by the BCR-ABL oncoprotein. Tyrosine kinase inhibitors (TKIs) for the STAT5-activating kinase JAK2 have been discussed as a treatment option fo ...

Nature Publishing Group2012

The Growing Arsenal of ATP-Competitive and Allosteric Inhibitors of BCR-ABL

Oliver Hantschel

The BCR-ABL fusion kinase is the driving mutation of chronic myelogenous leukemias and is also expressed in a subset of acute lymphoblastic leukemias. Recent advances in elucidating the structure, regulation, and signaling of BCR-ABL have led to the identi ...

Amer Assoc Cancer Research2012

Structure, regulation, signaling, and targeting of abl kinases in cancer

Oliver Hantschel

Abl kinases are prototypic cytoplasmic tyrosine kinases and are involved in a variety of chromosomal aberrations in different cancers. This causes the expression of Abl fusion proteins, such as Bcr-Abl, that are constitutively activated and drivers of tumo ...

2012

Mig6 is a sensor of EGF receptor inactivation that directly activates c-Abl to induce apoptosis during epithelial homeostasis

Oliver Hantschel

A fundamental aspect of epithelial homeostasis is the dependence on specific growth factors for cell survival, yet the underlying mechanisms remain obscure. We found an "inverse" mode of receptor tyrosine kinase signaling that directly links ErbB receptor ...

Cell Press - Elsevier2012